Skip to main content

Table 2 Survival characteristics of patients

From: The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas

 

mOS

in months

 

mOS

in months

p

Age

< 65

17.5

> 65

12

< 0.001

KPS

> 70

19

< 70

12

< 0.001

Sex

M

15

F

13

n.s.

EOR

GTR

15

STR

13

n.s.

Histo

AA

41

GBM

13

< 0.0001

MGMT

MGMT+

20

MGMT-

12

< 0.001

MGMT AA

MGMT+

41,5

MGMT-

18

n.d.

MGMT GBM

MGMT+

15

MGMT-

12

n.s.

IDH

IDH+

51

IDH-

13

< 0.0001

IDH AA

IDH+

54

IDH-

16

< 0.0001

IDH GBM

IDH+

11

IDH-

13

n.s.

EGFR

EGFR+

14

EGFR-

14

n.s.

EGFR AA

EGFR+

9

EGFR-

42

< 0.05

EGFR GBM

EGFR+

14

EGFR-

12

n.s.

IDH/MGMT

IDH+/MGMT+

46,5

IDH+/MGMT-

64

n.d.

IDH/MGMT

IDH+/MGMT+

46,5

IDH−/MGMT+

15

< 0,00001

IDH/MGMT

IDH+/MGMT+

46,5

IDH−/MGMT-

12

n.s.

IDH/MGMT

IDH−/MGMT+

15

IDH+/MGMT-

64

n.d.

IDH/MGMT

IDH−/MGMT+

15

IDH−/MGMT-

12

n.s.

IDH/MGMT

IDH+/MGMT-

64

IDH−/MGMT-

12

n.d.

  1. mOS median overall survival in months, p p-value by Logrank test with a value less than 0.05 indicating statistical significance, Histo histological diagnosis, AA anaplastic astrocytoma, GBM glioblastoma, GTR gross total resection, STR subtotal resection, M male, F female, n.s. not significant, n.d. not determined, KPS Karnofsky Performance Scale, EOR extent of resection, IDH+ IDH1 or IDH2 mutation, IDH- no IDH1 or IDH2 mutation, MGMT+ promoter methylation, MGMT- no promoter methylation, EGFR+ amplification, EGFR- no amplification
Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us